Masimo received FDA 510(k) clearance for AI-enabled opioid-induced respiratory depression (OIRD) detection on Radius VSM.

For over 35 years, Masimo has developed innovative monitoring technologies designed to improve patient outcomes and streamline clinical workflows. Today, we continue to build on that legacy—delivering AI-powered solutions to transform how clinicians care for their patients. From the NICU to the operating room to the home, our solutions help clinicians act with clarity and confidence—when and where it matters most. Masimo is proud to be part of Danaher, a global life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health. As part of Danaher, Masimo is connected to a uniquely broad ecosystem of expertise, technologies, and capabilities. Together, we partner closely with customers to help solve their toughest challenges with greater speed and certainty. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.